Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Simple Summary MicroRNAs (miRNAs) are small RNA molecules that regulate gene
expression by blocking translation or inducing degradation of specific gene transcripts. The …

Lung cancer remains a formidable global health burden, necessitating a comprehensive
understanding of the underlying molecular mechanisms driving its progression. Recently …

Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …

As a type of non-coding RNA of more than 200 nucleotides, long non-coding RNAs
(lncRNAs) lack protein coding ability and can regulate gene expression. MicroRNAs …

It is obvious that tumor cells have developed a number of strategies to escape immune
surveillance including an altered expression of various immune checkpoints, such as the …

Cancer immunotherapy is a major breakthrough in the history of tumor therapy in the last
decade. Immune checkpoint inhibitors blocking CTLA-4/B7 or PD-1/PD-L1 pathways have …

Within the non-coding genome landscape, long non-coding RNAs (lncRNAs) and their
secretion within exosomes are a window that could further explain the regulation, the …

Pancreatic cancer is the fourth leading cause of cancer death in the United States. The main
methods of treating pancreatic cancer are surgery and chemotherapy, but the treatment …

Cancer immunotherapy (CIT) is considered a revolutionary advance in the fight against
cancer. The complexity of the immune microenvironment determines the success or failure …